Sells health insurance in 14 states under an exclusive Blue Cross Blue Shield licence no competitor can obtain.
At a glance
- Depends onMidstream position: 5 outgoing, 6 incoming connections
- ScaleMarket cap is in the top 5% of all stocks globally
Sells health insurance in 14 states under an exclusive Blue Cross Blue Shield licence no competitor can obtain.
What this company is and how it runs — written from structure, not news.
Elevance Health sells health insurance to employers, Medicaid agencies, and Medicare enrollees across 14 states, and the core of the business is not pricing or network breadth but a trademark: the Blue Cross Blue Shield Association grants one exclusive licence per state, and Elevance holds those licences, so any buyer in those territories who wants coverage carrying the BCBS name must buy it from Elevance because no rival is legally permitted to offer it. That captive enrollment fills a large pool of premiums, and Elevance's pharmacy unit, CarelonRx, extracts a second layer of revenue from the same members by processing their prescription claims at a spread between what it pays wholesalers for drugs and what it charges the plan. The structure strains when medical costs rise sharply, because each of the 14 states runs its own rate-approval process on its own schedule, so Elevance must hold the required capital reserves across all 14 jurisdictions before it can collect the higher premiums to offset them. The whole arrangement pivots on a single relationship with the Association: if the Association were forced — by antitrust action or governance change — to allow other carriers to use the BCBS mark in those states, the enrollment preference that fills the premium pool would face direct competition for the first time, and the business model would lose the captive base it is built around.
How does this company make money?
Elevance collects monthly premiums from employer group contracts and individual marketplace plans. For Medicare Advantage members, the federal government pays a fixed amount per person per month. For Medicaid members, state governments pay a similar per-member monthly rate. On top of those insurance payments, CarelonRx earns money by paying drug wholesalers less for medications than the health plan reimburses — pocketing the difference on each prescription it processes.
What makes this company hard to replace?
Employer groups face 12 to 18 months of work to change health plan administrators because their benefits software and employee enrollment systems must be rebuilt around a new carrier. Provider contracts contain Blue Cross Blue Shield network participation clauses that would need to be individually renegotiated if employers moved to a non-BCBS insurer. Employers using CarelonRx face an additional barrier because its pharmacy benefit management is integrated directly into Elevance's claims system, meaning a switch would require replacing both the health plan and the drug benefit simultaneously.
What limits this company?
Each of the 14 states has its own insurance regulator who must approve any premium increase separately. When medical costs rise fast across all 14 states at once, Elevance cannot raise premiums everywhere immediately — it has to wait for each state's approval process to finish. During that wait, Elevance is still required by law to hold large cash reserves in each state, tying up money before the higher premiums arrive to replenish it.
What does this company depend on?
Elevance cannot operate without five named inputs: the Blue Cross Blue Shield Association's licensing agreements that grant trademark use in 14 states; annual contracts with CMS for Medicare Advantage and Part D coverage; state Medicaid managed care contracts, which are re-awarded roughly every 3 to 5 years; NCQA accreditation, which determines quality ratings; and rebate agreements with drug manufacturers that allow CarelonRx to manage which drugs appear on its formularies.
Who depends on this company?
Employer groups rely on Elevance to provide health benefits to their workers — if Elevance stopped mid-year, employees would lose access to their provider networks with no immediate replacement in place. Medicare Advantage members would lose their supplemental benefits and their assigned doctors, requiring CMS to reassign them to other carriers. State Medicaid agencies would face emergency transitions for some of the most vulnerable people they serve, including dual-eligible beneficiaries who qualify for both Medicare and Medicaid.
How does this company scale?
Adding more members spreads the fixed costs of claims-processing technology and actuarial modeling across a larger base, so those systems get cheaper per person as membership grows. Regional medical directors can extend provider network management without proportional cost increases. What does not scale away is geographic risk: Elevance can only pool risk across its 14 assigned states, so if medical costs spike in those specific markets, there is no national membership base to absorb the impact the way a coast-to-coast insurer could.
What external forces can significantly affect this company?
CMS sets the rules for Medicare Advantage star ratings, which determine whether Elevance receives federal bonus payments and whether members can be auto-enrolled — changes to that methodology directly affect revenue. Each state's decision to expand or contract Medicaid changes how many people Elevance can cover and how much federal matching money flows in. Regulations requiring more transparency in prescription drug rebate pricing would squeeze the spread that CarelonRx earns between wholesale drug costs and plan reimbursement rates.
Where is this company structurally vulnerable?
If the Blue Cross Blue Shield Association changed its exclusivity rules — pushed by an antitrust lawsuit, a federal regulation, or a vote within the Association itself — other insurers could enter Elevance's 14 states using the BCBS name. The moment employers and Medicaid agencies had a choice of BCBS-branded carriers, the enrollment preference Elevance currently enjoys by default would disappear. The premium pool that supports the reserves and funds the CarelonRx drug-pricing business would shrink as members moved to competitors.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in3 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Three observations describe the present configuration: the fast moving average sits below the slow moving average, the company has been profitable for three years, and cash-flow margin is elevated.
Three observations describe the present configuration: a high share of the trailing three years' weekly closes were higher than the prior week, the company has reported positive net income in each of the last five annual periods, and the book-value-increase-consistency composite over the trailing 5 years is elevated.
Three observations describe the present configuration: a high share of the trailing year's weekly closes were higher than the prior week, the company has reported positive net income in each of the last three annual periods, and the industry-benchmarked TTM operating cash flow margin is in the upper peer range.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
What the company actually pays, and whether its own cash supports it.
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company return capital?
Three dividend observations co-occur: the dividend-consistency composite is elevated, the dividend-stress composite is firing, and the common-dividends-to-FCF ratio is elevated. The combination records past payment regularity alongside two present-state coverage readings.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Four observations co-occur: free cash flow positive each of the last three fiscal years, revenue increased each of the last three fiscal years, trailing-statistics OCF margin elevated, and book value increased each of the last four fiscal years. The configuration describes multi-year fundamental persistence across cash flow, top line, margin, and equity accumulation.
Three observations align: revenue has increased every year over the trailing three years, receivables have increased every year over the trailing four years, and operating cash flow margin is on the industry-benchmarked scale. The picture is concurrent growth in revenue and receivables with peer-relative cash-conversion context.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
Screen for this company's dividend patterns
Find other companies where the same dividend readings fire.
CompanyGraph